{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:22:14Z","timestamp":1693214534651},"reference-count":36,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.clinthera.2014.09.021","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T23:11:59Z","timestamp":1414624319000},"page":"2082-2093","source":"Crossref","is-referenced-by-count":5,"title":["A Review of Sucroferric Oxyhydroxide for the Treatment of Hyperphosphatemia in Patients Receiving Dialysis"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01833494","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01850641","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01852682","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ava","family":"Bousher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Al-Makki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Shepler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"113","key":"10.1016\/j.clinthera.2014.09.021_bib1","first-page":"S50","article-title":"Prevention and treatment of Chronic Kidne Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"76","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2014.09.021_bib2","unstructured":"Velphoro [Prescribing Information]. Fresenius Medical Care North America. Waltham, MA, 2013."},{"key":"10.1016\/j.clinthera.2014.09.021_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5414\/CNP74004","article-title":"PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic disease","volume":"74","author":"Geisser","year":"2010","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.clinthera.2014.09.021_bib4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","article-title":"Randomized clinical trial of the iron- based phosphate binder PA21 in hemodialysis patients","volume":"8","author":"W\u00fcthrich","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2014.09.021_bib5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2014.09.021_bib6","doi-asserted-by":"crossref","DOI":"10.1007\/s40620-014-0080-1","article-title":"Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects","author":"Chong","year":"2014","journal-title":"J Nephrol"},{"key":"10.1016\/j.clinthera.2014.09.021_bib7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","article-title":"Arterial calcification in chronic kidney disease: key roles for calcium and phosphate","volume":"109","author":"Shanahan","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.clinthera.2014.09.021_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MNH.0b013e32836214d4","article-title":"Use of phosphate binders in chronic kidney disease","volume":"22","author":"Ketteler","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.clinthera.2014.09.021_bib9","unstructured":"USRDS. Altas of CKD and ESRD 2012. United States Renal Data Systems. USRDS Coordinating Center. Minneapolis, MN. http:\/\/www.usrds.org\/atlas.aspx. Accessed May 30, 2014"},{"key":"10.1016\/j.clinthera.2014.09.021_bib10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.ajkd.2011.12.025","article-title":"Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status","volume":"60","author":"Lopes","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2014.09.021_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40265-014-0224-6","article-title":"Next-generation phosphate binders: focus on iron-based binders","volume":"74","author":"Nastou","year":"2014","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.clinthera.2014.09.021_bib12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1592\/phco.29.5.554","article-title":"Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications","volume":"29","author":"Pai","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2014.09.021_bib13","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanism of anemia in CKD","volume":"10","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2014.09.021_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2369-14-199","article-title":"Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies","volume":"14","author":"Zheng","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.clinthera.2014.09.021_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1620\/tjem.227.217","article-title":"Biotin ameliorates muscle cramps of hemodialysis patients: a prospective trial","volume":"227","author":"Oguma","year":"2012","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.clinthera.2014.09.021_bib16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1753944713513061","article-title":"Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease","volume":"7","author":"Rastogi","year":"2013","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2014.09.021_bib17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2014.09.021_bib18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/art.20781","article-title":"Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis","volume":"52","author":"Garg","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2014.09.021_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000337087","article-title":"Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects","volume":"120","author":"Fraz\u00e3o","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.clinthera.2014.09.021_bib20","unstructured":"A long term study of PA21 in hemodialysis patients with hyperphosphatemia. NCT01833494. www.clinicaltrials.gov. Accessed June 3, 2014."},{"key":"10.1016\/j.clinthera.2014.09.021_bib21","unstructured":"A phase III study of PA21 in peritoneal dialysis patients with hyperphosphatemia. NCT01852682. www.clinicaltrials.gov. Accessed June 3, 2014."},{"key":"10.1016\/j.clinthera.2014.09.021_bib22","unstructured":"A phase III study of PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia. NCT01850641. www.clinicaltrials.gov. Accessed June 3, 2014."},{"key":"10.1016\/j.clinthera.2014.09.021_bib23","unstructured":"Genzyme Corporation. Renagel (sevelamer HCL) package insert. Cambridge, MA, 2004."},{"key":"10.1016\/j.clinthera.2014.09.021_bib24","unstructured":"Renagel. Red book online. Thompson Micromedex. Greenwood Village, CO. http:\/\/thompsonhc.com. Accessed May 25, 2014."},{"key":"10.1016\/j.clinthera.2014.09.021_bib25","unstructured":"Genzyme Corporation. Renvela (sevelamer carbonate) package insert. Cambridge, MA; 2011."},{"key":"10.1016\/j.clinthera.2014.09.021_bib26","unstructured":"Renvela. Red book online. Thompson Micromedex. Greenwood Village, CO. http:\/\/thompsonhc.com. Accessed May 25, 2014."},{"key":"10.1016\/j.clinthera.2014.09.021_bib27","unstructured":"Shire US Inc. Fosrenol (lanthanum carbonate) package insert. Wayne, PA; 2004"},{"key":"10.1016\/j.clinthera.2014.09.021_bib28","unstructured":"Fosrenol. Red book online. Thompson Micromedex. Greenwood Village, CO. http:\/\/thompsonhc.com. Accessed May 25, 2014."},{"key":"10.1016\/j.clinthera.2014.09.021_bib29","unstructured":"Nabi Biopharmaceuticals. PhosLo (R) (calcium acetate) package insert. Boca Raton, FL; 2003."},{"key":"10.1016\/j.clinthera.2014.09.021_bib30","unstructured":"Fresenius Medical Care North America. PhosLo(R) oral gelcaps (calcium acetate) package insert. Waltham, MA; 2011."},{"key":"10.1016\/j.clinthera.2014.09.021_bib31","unstructured":"Fresenius Medical Care North America. Phosryla(TM) oral solution (calcium acetate) package insert. Waltham, MA; 2011."},{"key":"10.1016\/j.clinthera.2014.09.021_bib32","unstructured":"PhosLo. Red book online. Thompson Micromedex. Greenwood Village, CO. http:\/\/thompsonhc.com. Accessed May 25, 2014."},{"key":"10.1016\/j.clinthera.2014.09.021_bib33","unstructured":"Calcium acetate. Red book online. Thompson Micromedex. Greenwood Village, CO. http:\/\/thompsonhc.com. Accessed May 25, 2014."},{"key":"10.1016\/j.clinthera.2014.09.021_bib34","unstructured":"GlaxoSmithKline. TUMS(R) Smoothies(TM) (Calcium carbonate) package insert. Moon Township, PA; 2010."},{"key":"10.1016\/j.clinthera.2014.09.021_bib35","unstructured":"Calcium carbonate. Red book online. Thompson Micromedex. Greenwood Village, CO. http:\/\/thompsonhc.com. Accessed May 25, 2014."},{"key":"10.1016\/j.clinthera.2014.09.021_bib36","unstructured":"Velphoro. Red book online. Thompson Micromedex. Greenwood Village, CO. http:\/\/thompsonhc.com. Accessed May 25, 2014."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814006134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814006134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T21:05:30Z","timestamp":1530219930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814006134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0149291814006134"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.09.021","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}